147 related articles for article (PubMed ID: 15206943)
21. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
Evans JC; Malhotra M; Cryan JF; O'Driscoll CM
Br J Pharmacol; 2016 Nov; 173(21):3041-3079. PubMed ID: 27526115
[TBL] [Abstract][Full Text] [Related]
22. Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III.
Hlouchova K; Barinka C; Konvalinka J; Lubkowski J
FEBS J; 2009 Aug; 276(16):4448-62. PubMed ID: 19678840
[TBL] [Abstract][Full Text] [Related]
23. The cloning and characterization of a second brain enzyme with NAAG peptidase activity.
Bzdega T; Crowe SL; Ramadan ER; Sciarretta KH; Olszewski RT; Ojeifo OA; Rafalski VA; Wroblewska B; Neale JH
J Neurochem; 2004 May; 89(3):627-35. PubMed ID: 15086519
[TBL] [Abstract][Full Text] [Related]
24. Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods.
Klusák V; Barinka C; Plechanovová A; Mlcochová P; Konvalinka J; Rulísek L; Lubkowski J
Biochemistry; 2009 May; 48(19):4126-38. PubMed ID: 19301871
[TBL] [Abstract][Full Text] [Related]
25. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase.
Davis MI; Bennett MJ; Thomas LM; Bjorkman PJ
Proc Natl Acad Sci U S A; 2005 Apr; 102(17):5981-6. PubMed ID: 15837926
[TBL] [Abstract][Full Text] [Related]
26. Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility.
Divyya S; Naushad SM; Addlagatta A; Murthy PV; Reddy ChR; Digumarti RR; Gottumukkala SR; Kumar A; Rammurti S; Kutala VK
Gene; 2012 Apr; 497(2):273-9. PubMed ID: 22310383
[TBL] [Abstract][Full Text] [Related]
27. Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II.
Navrátil M; Ptáček J; Šácha P; Starková J; Lubkowski J; Bařinka C; Konvalinka J
FEBS J; 2014 Jul; 281(14):3228-42. PubMed ID: 24863754
[TBL] [Abstract][Full Text] [Related]
28. Molecular modeling of the interactions of glutamate carboxypeptidase II with its potent NAAG-based inhibitors.
Rong SB; Zhang J; Neale JH; Wroblewski JT; Wang S; Kozikowski AP
J Med Chem; 2002 Sep; 45(19):4140-52. PubMed ID: 12213057
[TBL] [Abstract][Full Text] [Related]
29. A novel PSMA/GCPII-deficient mouse model shows enlarged seminal vesicles upon aging.
Vorlová B; Sedlák F; Kašpárek P; Šrámková K; Malý M; Zámečník J; Šácha P; Konvalinka J
Prostate; 2019 Feb; 79(2):126-139. PubMed ID: 30256431
[TBL] [Abstract][Full Text] [Related]
30. Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate.
Bacich DJ; Ramadan E; O'Keefe DS; Bukhari N; Wegorzewska I; Ojeifo O; Olszewski R; Wrenn CC; Bzdega T; Wroblewska B; Heston WD; Neale JH
J Neurochem; 2002 Oct; 83(1):20-9. PubMed ID: 12358725
[TBL] [Abstract][Full Text] [Related]
31. GCPII variants, paralogs and orthologs.
Hlouchová K; Navrátil V; Tykvart J; Sácha P; Konvalinka J
Curr Med Chem; 2012; 19(9):1316-22. PubMed ID: 22304710
[TBL] [Abstract][Full Text] [Related]
32. Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy.
Chaloupková Z; Balzerová A; Bařinková J; Medříková Z; Šácha P; Beneš P; Ranc V; Konvalinka J; Zbořil R
Anal Chim Acta; 2018 Jan; 997():44-51. PubMed ID: 29149993
[TBL] [Abstract][Full Text] [Related]
33. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.
Bařinka C; Rojas C; Slusher B; Pomper M
Curr Med Chem; 2012; 19(6):856-70. PubMed ID: 22214450
[TBL] [Abstract][Full Text] [Related]
34. Clinical utility of genetic variants of glutamate carboxypeptidase II in predicting breast cancer and prostate cancer risk.
Naushad SM; Shree Divyya P; Janaki Ramaiah M; Alex Stanley B; Prasanna Lakshmi S; Vishnupriya J; Kutala VK
Cancer Genet; 2015 Nov; 208(11):552-8. PubMed ID: 26471812
[TBL] [Abstract][Full Text] [Related]
35. Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities.
Novakova Z; Cerny J; Choy CJ; Nedrow JR; Choi JK; Lubkowski J; Berkman CE; Barinka C
FEBS J; 2016 Jan; 283(1):130-43. PubMed ID: 26460595
[TBL] [Abstract][Full Text] [Related]
36. Rationally designed sulfamides as glutamate carboxypeptidase II inhibitors.
Choy CJ; Fulton MD; Davis AL; Hopkins M; Choi JK; Anderson MO; Berkman CE
Chem Biol Drug Des; 2013 Nov; 82(5):612-9. PubMed ID: 23773397
[TBL] [Abstract][Full Text] [Related]
37. Recombinant glutamate carboxypeptidase II (prostate specific membrane antigen--PSMA)--cellular localization and bioactivity analyses.
Meighan MA; Dickerson MT; Glinskii O; Glinsky VV; Wright GL; Deutscher SL
J Protein Chem; 2003 May; 22(4):317-26. PubMed ID: 13678295
[TBL] [Abstract][Full Text] [Related]
38. Blocking glutamate carboxypeptidase II inhibits glutamate excitotoxicity and regulates immune responses in experimental autoimmune encephalomyelitis.
Ha D; Bing SJ; Ahn G; Kim J; Cho J; Kim A; Herath KH; Yu HS; Jo SA; Cho IH; Jee Y
FEBS J; 2016 Sep; 283(18):3438-56. PubMed ID: 27444540
[TBL] [Abstract][Full Text] [Related]
39. Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain.
Kim MJ; Chae SS; Koh YH; Lee SK; Jo SA
FASEB J; 2010 Nov; 24(11):4491-502. PubMed ID: 20624932
[TBL] [Abstract][Full Text] [Related]
40. Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors.
Barinka C; Novakova Z; Hin N; Bím D; Ferraris DV; Duvall B; Kabarriti G; Tsukamoto R; Budesinsky M; Motlova L; Rojas C; Slusher BS; Rokob TA; Rulíšek L; Tsukamoto T
Bioorg Med Chem; 2019 Jan; 27(2):255-264. PubMed ID: 30552009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
